Updates are available Correction dated 2023-11-18
Click to view Correction: https://doi.org/10.1007/s00262-023-03575-4
-
Authors
Tachiki, Lisa May Ling http://orcid.org/0000-0001-8057-8029
Hippe, Daniel S.
Williams Silva, Karly
Hall, Evan Thomas
McCamy, William
Fritzsche, Dane
Perdue, Andrea
Majovski, Julia
Pulliam, Thomas
Goldstein, Daniel A.
Veatch, Joshua
Ho, Joel
Nghiem, Paul T.
Thompson, John A.
Bhatia, Shailender http://orcid.org/0000-0002-3816-2238
-
Funding
Funding for this research was provided by:
National Cancer Institute (T32 CA951537, P01 CA225517, P01 CA225517, P01 CA225517)
Kuni Foundation (A173040)
University of Washington (MCC patient gift fund)
National Institutes of Health/NCI Cancer Center Support Grant (P30 CA015704, P30 CA015704)
Kelsey Dickson Merkel Cell Carcinoma Fund
- License Information
-
More Information
Article History
Received: 21 June 2023
Accepted: 30 August 2023
First Online: 21 September 2023
Change Date: 18 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-023-03575-4
Declarations
:
: LT reports research grant funding (to institution) from Seagen and Merck; travel support from ASCO Merit Award. DH reports research grant funding from GE Healthcare. EH reports research grant funding (to institution) from Treatment Technologies and Insights, Neoleukin Technologies, ImCheck Therapeutics, Nektar, Replimune, and Nikang Therapeutics. JT reports consulting roles from Alpine, Bristol-Myer Squibb, and Mabquest; research grants (to institution) from Pfizer, Agensys, Five Prime Therapeutics, Trillium Therapeutics, Novarits, Xencor, Incyte, and PMV Pharma. JV reports stock and ownership, funding and intellectual property licensed to Lyell Immunopharma. DG reports stock and ownership interests in TailorMed and Vivio Health; consulting or advisory roles in Vivio Health; funding from MSD, BMS, and Janssen. PN reports consulting roles at 4SC, EMD Serono, Merck Sharp & Dohme, Pfizer, Pfizer/EMD Serono, and Sanofi/Regeneron; research grant funding from Bristol-Meyer Squibb and EMD Serono; patent filed for "Merkel cell polyomavirus T antigen-specific TCRs and uses thereof" and patent pending for high affinity T cell receptors that target the Merkel polyomavirus; travel expenses from Merck Sharp & Dohme and Sanofi/Regeneron. SB reports Advisory Board/Consultant (with honorarium) for Bristol Myers Squibb, Castle biosciences, EMD Serono, Exicure, Genentech, Sanofi-Genzyme and Incyte; Research Grants (to institution) from 4SC, Amphiyena Therapeutics, Bristol Myers Squibb, Checkmate, EMD Serono, Exicure, Immune Design, Incyte, Merck, NantKwest, Nektar, Novartis, OncoSec, Regeneron, Xencor; Stock/Equity in Moderna.
: Approval to conduct this study was obtained from the Fred Hutchinson Institutional Review Board. This study was conducted in accordance with the Declaration of Helsinki provisions. A consent was not required due to the retrospective nature of the study and the fact that there was no way to identify any of the subjects.
: The authors affirm that patient provided informed consent for publication of the images in Fig. InternalRef removedA, B and C
